Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. - Wikidata - wikimedia - TriplyDB

Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma.

Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma.

http://www.wikidata.org/entity/Q34107623

about

sameAs

Inhibition of human pancreatic ribonuclease by the human ribonuclease inhibitor protein Ranpirnase Interferes with NF-κB Pathway and MMP9 Activity, Inhibiting Malignant Mesothelioma Cell Invasiveness and Xenograft Growth Ribonucleases as novel chemotherapeutics : the ranpirnase example X-ray structure of two crystalline forms of a streptomycete ribonuclease with cytotoxic activity Structural Basis for Catalysis by Onconase Cytotoxic ribonucleases: molecular weapons and their targets Ribonuclease inhibitor: structure and function BTS statement on malignant mesothelioma in the UK, 2007.Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnase.Onconase responsive genes in human mesothelioma cells: implications for an RNA damaging therapeutic agent.Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancer The cytotoxic ribonuclease onconase targets RNA interference (siRNA).Towards tricking a pathogen's protease into fighting infection: the 3D structure of a stable circularly permuted onconase variant cleavedby HIV-1 protease Local controlled delivery of anti-neoplastic RNAse to the brain Mesothelioma: a review.Chemotherapy options and new advances in malignant pleural mesothelioma.Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma.Cancer therapy with radiolabeled and drug/toxin-conjugated antibodies.A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients.The hallmarks of cancer: a long non-coding RNA point of view.Ranpirnase--an antitumour ribonuclease: its potential role in malignant mesothelioma.Malignant pleural mesothelioma: a comprehensive review.Impact of antibody framework residue VH-71 on the stability of a humanised anti-MUC1 scFv and derived immunoenzyme.Emerging drugs for mesothelioma.Ranpirnase as a potential antitumor ribonuclease treatment for mesothelioma and other malignancies.Malignant pleural mesothelioma: current and future perspectives Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma Ribonucleases as potential modalities in anticancer therapy Malignant pleural mesothelioma: current treatments and emerging drugs.Evaluation of human pancreatic RNase as effector molecule in a therapeutic antibody platform.A molecular targeting against nuclear factor-κB, as a chemotherapeutic approach for human malignant mesothelioma.Translational therapies for malignant pleural mesothelioma.Translational advances in pleural malignancies.Antibody-enzyme fusion proteins for cancer therapy.Review on clinical trials of targeted treatments in malignant mesothelioma.Metastases to the oral region from pleural mesothelioma: Clinicopathologic review.Recent advances in the application of antibodies as therapeutics.Malignant pleural mesothelioma: from the bench to the bedside.

P2860

Q24299746-65D1DBDD-B46E-4EB3-A8B5-2DCAFE65DD87 Q24299746-D3BD4D35-7A8C-4FCF-973C-98A7ED101C93 Q24612464-E303A03D-59EB-4253-9248-678F6F4DD84C Q24612464-F40B0D07-83EB-4B29-848D-F74F8C1DBECC Q24650138-4693E56A-B536-41D5-ADC7-39A0C36EBA88 Q24650138-A5D28EB5-A2BF-4D71-863C-433167DAA63E Q27639646-31366CA0-FD7A-44AB-95B3-9C94C7A399C8 Q27649038-451B3ADF-2B05-49DE-9E29-82A156328547 Q27649038-94D7876C-D5B4-412B-8FAD-A851192F9B74 Q28189322-DF0FDB94-379E-43D5-84A4-66BEE8BB5E6E Q28272410-4833696C-1F16-411E-9362-6F6C03322EC8 Q28272410-912C97A6-5EFE-4C8E-AC52-5F63BEF3EA9F Q30478994-3CEBCF57-33F0-4CB1-94CB-93DD6414CE19 Q30478994-ADF7DAC2-A784-45EC-8F72-1064E133EB62 Q33227741-61261546-42EF-4001-BC58-537156F0CDEA Q33529876-77BB828D-3C6D-4E92-9575-B7F812AC7450 Q33529876-CB2B8C38-F93C-4E52-B488-F8B549B079BC Q33587482-8C91BA32-5F17-4201-A674-F437C482D0F5 Q33587482-CED7C0A1-29A0-4F41-BAB1-CF9CBEF61FD1 Q34014208-398D8FB3-84AF-47E6-B828-2756A5107993 Q34014208-6F299093-54B6-46F2-9A3D-9A4086EF2CA8 Q34563323-2CE21D4E-B20D-4598-9D27-36AED237840F Q34563323-3688E828-C0FA-4667-A28A-9953DF68AE6B Q34892518-36E97285-2157-48FC-B194-8E5BC00B2365 Q34892518-6A792878-EDE1-4DFE-AF74-485DAF41678A Q35839385-A48540B1-892C-4E98-870A-7E1661A6AB38 Q35839385-FD42B0A3-AEEA-4CCF-A2F8-B3C459CB913D Q36022779-744F0489-C7A3-4605-99DE-95C937580ADA Q36162505-3DDCA24E-77CC-4EA8-B3A7-557B9B26B355 Q36200153-3A52728A-A7C2-4594-B533-8F9FA7425C59 Q36269852-0E092D47-5969-4F7B-953E-F837477444A7 Q36269852-117B349A-337F-4CD4-9405-34F8791EF385 Q36322368-373237B8-CAC2-4526-9E48-8E2B65D61C60 Q36322368-9E2DB611-1A4D-4409-A52F-5D90C2B17644 Q36391951-9CFEFFF3-A0AF-4F25-A55E-5B722E922859 Q36391951-AC4C12FD-459A-4FFE-AE4C-A8F73358EC48 Q36425940-A874BE92-21B8-47EE-85D1-8A7E651A0E0B Q36639812-0E3425AD-AFD7-417E-B7E8-1B3DC46B6F97 Q36695056-54EA64B9-91C5-4DF8-9671-81DEA2B4063D Q36695056-683FC3CB-FA19-4762-BB8F-E05F2B24517C

P2860

Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma.

http://www.wikidata.org/entity/Q34107623

description

2002 nî lūn-bûn

@nan

2002 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Phase II trial of a single wee ...... ctable malignant mesothelioma.

@ast

Phase II trial of a single wee ...... ctable malignant mesothelioma.

@en

Phase II trial of a single wee ...... ctable malignant mesothelioma.

@nl

type

label

Phase II trial of a single wee ...... ctable malignant mesothelioma.

@ast

Phase II trial of a single wee ...... ctable malignant mesothelioma.

@en

Phase II trial of a single wee ...... ctable malignant mesothelioma.

@nl

altLabel

Phase II Trial of a Single Wee ...... ectable Malignant Mesothelioma

@en

Phase II Trial of a Single Wee ...... ectable Malignant Mesothelioma

@nl

prefLabel

Phase II trial of a single wee ...... ctable malignant mesothelioma.

@ast

Phase II trial of a single wee ...... ctable malignant mesothelioma.

@en

Phase II trial of a single wee ...... ctable malignant mesothelioma.

@nl

P1433

Q34107623-17C0368C-5BF6-453C-8C07-AEAD57F7E2F1

P1476

Q34107623-9119371E-65D1-49E9-A154-D34B8E3303A7

Q34107623-A7CA47BC-34D5-4EDF-B35D-7C57B45E4605

P2093

Q34107623-3B867AB1-94F3-4DC5-A16C-257DCAADFA6D

Q34107623-441EA983-3928-4C21-83D5-D5CEBB22FBFD

Q34107623-4E80665F-2E8C-472B-B974-C8A679492152

Q34107623-55358CB0-1F65-4AD8-9D93-4F4BED64170B

Q34107623-556741FD-AB73-41A9-8BD1-4C1B2B95678E

Q34107623-56711F36-482D-4855-96BD-E72A9AF56191

Q34107623-5B1B440B-1A8E-455B-BAAF-5D0D87967AB3

Q34107623-68AFA152-7FAA-4C23-9D30-912385406E9B

Q34107623-69BBD490-03A9-4A7C-AF89-5F40921DD911

Q34107623-72056312-C7A2-4AF1-AC8B-F652B6013438

P304

Q34107623-04001274-E3C8-43BD-81F1-792C4819D764

P31

Q34107623-79AD822C-B22E-4F2D-870C-99FEF023086C

P356

Q34107623-759D6743-D0F0-40F9-BDDD-1FFD3624EBF5

Q34107623-CBF77530-033E-44A3-85A9-B19C7F1EB85F

P407

Q34107623-DF0C1427-FB3D-4FB7-BCA2-7D4D5FF818DB

P433

Q34107623-BD2C6298-D204-4ADF-B530-BF27260D0962

P478

Q34107623-95B9B33B-EAA1-4C78-A840-5EB7F50BBBFD

P577

Q34107623-03D16BF8-F7A5-4CA9-A948-451A1D2B6EEF

Q34107623-749937AA-414D-4A3E-BF28-E9C4CCC4812F

P698

Q34107623-04FD6418-2594-4C54-AECF-999014CA14CC

P921

Q34107623-060385A7-1641-4FF4-A820-2721B38E795B

Q34107623-6C3C0804-2FD8-4651-AAEB-4C6AEC8EF6F2

P356

JCO.2002.20.1.274

P1433

Journal of Clinical Oncology

P1476

Phase II Trial of a Single Wee ...... ectable Malignant Mesothelioma

@en

Phase II trial of a single wee ...... ctable malignant mesothelioma.

@en

P2093

Abraham Mittelman

http://www.w3.org/2001/XMLSchema#string

Carmelo Puccio

http://www.w3.org/2001/XMLSchema#string

Hoo Chun

http://www.w3.org/2001/XMLSchema#string

John J Costanzi

http://www.w3.org/2001/XMLSchema#string

John J. Costanzi

http://www.w3.org/2001/XMLSchema#string

Kuslima Shogen

http://www.w3.org/2001/XMLSchema#string

Nicholas J Vogelzang

http://www.w3.org/2001/XMLSchema#string

Nicholas J. Vogelzang

http://www.w3.org/2001/XMLSchema#string

Robert Fine

http://www.w3.org/2001/XMLSchema#string

Robert N Taub

http://www.w3.org/2001/XMLSchema#string

P304

274-281

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.20.1.274

http://www.w3.org/2001/XMLSchema#string

10.1200/JCO.2002.20.1.274

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2002-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11773179

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial